CashuPluri Advances Cell Therapy, Transforming Regenerative Medicine for Degenerative Diseases2 months ago
benzinga.comU.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contractover 1 year ago
benzinga.comNovel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scaleover 1 year ago
finance.yahoo.comPluri Third Quarter 2024 Earnings: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)over 1 year ago
benzinga.comUnleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatmentover 1 year ago
benzinga.comBreakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Methodover 1 year ago
finance.yahoo.comGlobal Regenerative Medicine Industry Research 2023-2028: Market Driven by Wide Scope in New Therapeutic Areas and Collaborations and Partnershipsover 1 year ago
benzinga.comPluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Boardalmost 2 years ago
finance.yahoo.comPluri Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)almost 2 years ago